Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Oncternal Therapeutics, Inc. | onct-ex322_16.htm |
| EX-32.1 - EX-32.1 - Oncternal Therapeutics, Inc. | onct-ex321_8.htm |
| EX-31.2 - EX-31.2 - Oncternal Therapeutics, Inc. | onct-ex312_15.htm |
| EX-31.1 - EX-31.1 - Oncternal Therapeutics, Inc. | onct-ex311_7.htm |
| EX-10.37 - EX-10.37 - Oncternal Therapeutics, Inc. | onct-ex1037_578.htm |
| EX-10.14 - EX-10.14 - Oncternal Therapeutics, Inc. | onct-ex1014_496.htm |
| 10-K - 10-K - Oncternal Therapeutics, Inc. | onct-10k_20201231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
Oncternal Therapeutics, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-221040, 333-204932, 333-201132 and 333-197911) and Forms S-8 (Nos. 333-233288, 333-223742, 333-210220, 333-208744, 333-188377, 333-165507, 333-149661, 333-136527, 333-118882, and 333-112576) of Oncternal Therapeutics, Inc., of our report dated March 11, 2021, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.
/s/ BDO USA, LLP
San Diego, California
March 11, 2021